Shares of Checkpoint Therapeutics (NASDAQ:CKPT) have been given a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.
Brokerages have set a 1 year consensus price objective of $15.50 for the company and are expecting that the company will post ($0.19) earnings per share for the current quarter, according to Zacks. Zacks has also given Checkpoint Therapeutics an industry rank of 183 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research lowered Checkpoint Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, March 22nd.
Shares of CKPT opened at $4.30 on Monday. Checkpoint Therapeutics has a 52 week low of $3.20 and a 52 week high of $13.00.
Checkpoint Therapeutics (NASDAQ:CKPT) last posted its quarterly earnings results on Friday, March 16th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.01. Checkpoint Therapeutics had a negative return on equity of 102.39% and a negative net margin of 1,316.72%. The business had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.35 million. equities research analysts anticipate that Checkpoint Therapeutics will post -0.84 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/04/09/analysts-anticipate-checkpoint-therapeutics-ckpt-to-announce-0-19-eps.html.
Checkpoint Therapeutics Company Profile
Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. Its pipeline consists of human, immuno-oncology, and checkpoint inhibitor antibodies that target programmed death-ligand 1; glucocorticoid-induced TNFR-related protein; and carbonic anhydrase IX.
Get a free copy of the Zacks research report on Checkpoint Therapeutics (CKPT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.